Nanjing Hicin Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Nanjing Hicin Pharmaceutical's earnings have been declining at an average annual rate of -5.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 14% per year. Nanjing Hicin Pharmaceutical's return on equity is 4.1%, and it has net margins of 8.4%.
Key information
-5.8%
Earnings growth rate
-5.8%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -14.0% |
Return on equity | 4.1% |
Net Margin | 8.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump
Aug 15We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve
May 01Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues
Mar 08Revenue & Expenses Breakdown
How Nanjing Hicin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 493 | 42 | 293 | 43 |
31 Mar 24 | 505 | 37 | 299 | 49 |
31 Dec 23 | 518 | 36 | 315 | 47 |
30 Sep 23 | 525 | 35 | 331 | 36 |
30 Jun 23 | 520 | 34 | 331 | 31 |
31 Mar 23 | 493 | 32 | 318 | 16 |
01 Jan 23 | 526 | 32 | 330 | 18 |
30 Sep 22 | 504 | 278 | 330 | 17 |
30 Jun 22 | 529 | 282 | 351 | 16 |
31 Mar 22 | 567 | 285 | 386 | 19 |
01 Jan 22 | 578 | 286 | 405 | 22 |
30 Sep 21 | 612 | 35 | 411 | 27 |
30 Jun 21 | 647 | 40 | 421 | 31 |
31 Mar 21 | 702 | 52 | 428 | 31 |
31 Dec 20 | 706 | 55 | 422 | 32 |
30 Sep 20 | 788 | 68 | 458 | 36 |
30 Jun 20 | 845 | 81 | 499 | 32 |
31 Mar 20 | 880 | 92 | 536 | 33 |
31 Dec 19 | 925 | 97 | 567 | 36 |
30 Sep 19 | 871 | 98 | 548 | 38 |
30 Jun 19 | 826 | 95 | 525 | 41 |
31 Mar 19 | 759 | 89 | 483 | 46 |
31 Dec 18 | 712 | 83 | 465 | 38 |
30 Sep 18 | 679 | 82 | 441 | 33 |
30 Jun 18 | 624 | 77 | 376 | 50 |
31 Mar 18 | 543 | 75 | 314 | 35 |
31 Dec 17 | 455 | 66 | 244 | 31 |
30 Sep 17 | 388 | 60 | 191 | 22 |
30 Jun 17 | 333 | 53 | 168 | 0 |
31 Mar 17 | 305 | 48 | 146 | 0 |
31 Dec 16 | 281 | 45 | 130 | 0 |
30 Sep 16 | 262 | 48 | 174 | 0 |
31 Dec 15 | 221 | 40 | 85 | 0 |
31 Dec 14 | 198 | 34 | 73 | 0 |
31 Dec 13 | 170 | 33 | 55 | 0 |
Quality Earnings: 300584 has high quality earnings.
Growing Profit Margin: 300584's current net profit margins (8.4%) are higher than last year (6.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300584's earnings have declined by 5.8% per year over the past 5 years.
Accelerating Growth: 300584's earnings growth over the past year (21.6%) exceeds its 5-year average (-5.8% per year).
Earnings vs Industry: 300584 earnings growth over the past year (21.6%) exceeded the Pharmaceuticals industry 0.3%.
Return on Equity
High ROE: 300584's Return on Equity (4.1%) is considered low.